<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title>Molecular Vision</journal-title><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">62</article-id><article-id pub-id-type="publisher-id">2008MOLVIS0366</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Steinbrugger</surname><given-names>Iris</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Haas</surname><given-names>Anton</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maier</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Renner</surname><given-names>Wilfried</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mayer</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Werner</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wedrich</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>El-Shabrawi</surname><given-names>Yosuf</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schmut</surname><given-names>Otto</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Weger</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Ophthalmology, Medical University of Graz, Graz, Austria</aff><aff id="aff2"><label>2</label>Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Martin Weger, Department of Ophthalmology, Medical University of Graz, Auenbruggerplatz 4, A-8036 Graz, Austria; Phone: ++43 316 385 2394; FAX: ++43 316 385 3164; email: <ext-link ext-link-type="uri" xlink:href="mailto:martin.weger@meduni-graz.at">martin.weger@meduni-graz.at</ext-link></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>27</day><month>3</month><year>2009</year></pub-date><volume>15</volume><fpage>609</fpage><lpage>618</lpage><history><date date-type="received"><day>13</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>02</day><month>3</month><year>2009</year></date></history><permissions><copyright-year>2009</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title>Purpose</title><p>Branch retinal vein occlusion (BRVO) is a common vision-threatening disease. Compression of the underlying retinal vein due to increased rigidity of the crossing artery has been implicated in the pathogenesis of BRVO. Among others, arterial hypertension and hypercholesterolemia, both of which contribute to atherogenesis, have been identified as risk factors. Atherosclerosis itself is a chronic low-grade inflammatory disease with a distinct pro-inflammatory cytokine pattern. In addition to their role in atherogenesis, some cytokines have been shown to exert procoagulatory effects, and may thus contribute to the development of BRVO by a second mechanism. Gene polymorphisms affecting the expression of inflammation-related cytokines are therefore candidates as potential risk factors for BRVO. The purpose of the present study was to investigate hypothesized associations between cytokine gene polymorphisms and the presence of BRVO.</p></sec><sec sec-type="methods"><title>Methods</title><p>The study comprised 398 patients with BRVO and 355 control subjects. Using 5&#x02032;exonuclease assays (TaqMan), genotypes of the following functional single nucleotide polymorphisms were determined: interleukin 1 beta (<italic>IL1B</italic>) &#x02212;511C&#x0003e;T, interleukin 1 receptor antagonist (<italic>IL1RN</italic>) 1018T&#x0003e;C, interleukin 4 (<italic>IL4</italic>) &#x02212;584C&#x0003e;T, interleukin 6 (<italic>IL6</italic>) &#x02212;174G&#x0003e;C, interleukin 8 (<italic>IL8</italic>) &#x02212;251A&#x0003e;T, interleukin 10 (<italic>IL10</italic>) &#x02212;592C&#x0003e;A, interleukin 18 (<italic>IL18</italic>) 183A&#x0003e;G, tumor necrosis factor (<italic>TNF</italic>) &#x02212;308G&#x0003e;A, monocyte chemoattractant protein 1 (<italic>CCL2</italic>) &#x02212;2518A&#x0003e;G, and RANTES (<italic>CCL5</italic>) &#x02212;403G&#x0003e;A.</p></sec><sec><title>Results</title><p>Neither genotype distributions nor allele frequencies of any of the investigated polymorphisms differed significantly between BRVO patients and controls (p&#x0003e;0.05). Arterial hypertension was found to be significantly more prevalent in BRVO patients than in controls (p&#x0003c;0.001). In a logistic regression analysis presence of arterial hypertension was associated with an odds ratio of 3.33 (95% confidence interval: 2.42&#x02013;4.57) for BRVO.</p></sec><sec><title>Conclusions</title><p>As none of the investigated gene variants was significantly more prevalent in BRVO patients than among control subjects, our data suggest that these polymorphisms themselves are unlikely major risk factors for BRVO.</p></sec></abstract><custom-meta-wrap><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Weger</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Branch retinal vein occlusion (BRVO) is a vision-threatening disease, commonly affecting patients older than 60 years. It frequently occurs at an arteriovenous crossing site, where the retinal vein shares a common adventitial sheath with the retinal artery [<xref ref-type="bibr" rid="r1">1</xref>,<xref ref-type="bibr" rid="r2">2</xref>]. Increased rigidity of the crossing artery resulting from atherosclerotic disease has been suggested to cause compression of the underlying vein, resulting in turbulent blood flow, endothelial damage, and thrombus formation [<xref ref-type="bibr" rid="r3">3</xref>]. Consequently, arterial hypertension, elevated plasma homocysteine concentrations, and hypercholesterolemia, all of which are known to contribute to atherogenesis, have been identified as BRVO risk factors [<xref ref-type="bibr" rid="r4">4</xref>-<xref ref-type="bibr" rid="r7">7</xref>].</p><p>Atherosclerosis itself is a chronic low-grade inflammatory disease, which is characterized by the recruitment of both monocytes and T lymphocytes to the site of inflammation and a distinct pro-inflammatory T<sub>H</sub>1 cytokine pattern [<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r9">9</xref>]. Animal experiments have provided some evidence that a lack of anti-inflammatory cytokines promotes atherogenesis, whereas deficiency of pro-inflammatory cytokines is associated with reduced atherosclerosis [<xref ref-type="bibr" rid="r10">10</xref>-<xref ref-type="bibr" rid="r12">12</xref>]. Importantly, cytokines and chemokines such as interleukin 1 beta (IL-1&#x003b2;), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor alpha (TNF-&#x003b1;), and monocyte chemoattractant protein 1 (MCP-1) have also been reported to affect hemostasis, and may thus contribute to thrombus formation [<xref ref-type="bibr" rid="r13">13</xref>-<xref ref-type="bibr" rid="r17">17</xref>].</p><p>Single nucleotide polymorphisms (SNPs) affecting the expression of cytokines or chemokines previously implicated in atherogenesis as well as activation of the coagulation cascade are thus potential risk factors for BRVO. Nevertheless, they have not yet been investigated among BRVO patients. Consequently, in the present study, functional gene polymorphisms encoding the following cytokines or chemokines were chosen as candidate risk factors.</p><p>The pro-inflammatory cytokine IL-1&#x003b2; exerts strong pro-atherogenic effects by enhancing expression of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on endothelial cells. Furthermore, IL-1&#x003b2; induces the synthesis of chemokines, such as IL-8 and MCP-1, and thus facilitates the transendothelial migration of inflammatory cells [<xref ref-type="bibr" rid="r18">18</xref>,<xref ref-type="bibr" rid="r19">19</xref>]. Additional evidence for its role in atherosclerosis comes from an animal model showing that in apoE-deficient mice a lack of IL-1&#x003b2; is associated with decreased severity of atherosclerosis [<xref ref-type="bibr" rid="r20">20</xref>]. IL-1&#x003b2; also exerts procoagulatory effects by increasing the expression of tissue factor, which itself plays an essential role in the activation of the extrinsic pathway of the coagulation cascade [<xref ref-type="bibr" rid="r13">13</xref>]. Furthermore, increased expression of IL-1&#x003b2; downregulates tissue&#x02013;type plasminogen activator (t-PA), and thus impairs fibrinolysis [<xref ref-type="bibr" rid="r21">21</xref>]. A gene polymorphism, characterized by a C to T transition at position &#x02013;511 of the <italic>IL1B</italic> gene (<italic>IL1B</italic>&#x02212;511C&#x0003e;T, rs16944), affects the expression of <italic>IL1B</italic>. Iacoviello and coworkers [<xref ref-type="bibr" rid="r22">22</xref>] found that stimulation with lipopolysaccharide (LPS) produced a significant decrease in tissue factor expression as well as IL-1&#x003b2; release in mononuclear cells from participants carrying the &#x02212;511TT genotype compared to those homozygous for the &#x02212;511C allele.</p><p>By binding to the IL-1 receptor without transmitting the agonist signal, the interleukin 1 receptor antagonist (IL-1Ra) counter-regulates IL-1&#x003b2; activity [<xref ref-type="bibr" rid="r18">18</xref>]. Animal models have demonstrated that deficiency of IL-1Ra affects the development of atherosclerotic lesions [<xref ref-type="bibr" rid="r23">23</xref>,<xref ref-type="bibr" rid="r24">24</xref>]. Recently, a polymorphism within the gene encoding IL-1Ra (<italic>IL1RN</italic> 1018T&#x0003e;C, rs4251961) has been associated with both decreased IL-1Ra production and increased IL-6 and C-reactive protein (CRP) plasma concentrations [<xref ref-type="bibr" rid="r25">25</xref>].</p><p>Several studies support an important pathogenic role of interleukin 4 (IL-4) in atherogenesis. IL-4 mediates proatherogenic pathways by both increasing the expression of MCP-1, IL-6, VCAM-1, and by upregulation of 15&#x02013;lipoxygenase, which itself plays an essential role in oxidizing low-density lipoprotein (LDL) to its atherogenic form [<xref ref-type="bibr" rid="r26">26</xref>-<xref ref-type="bibr" rid="r29">29</xref>]. Furthermore, mice experiments have provided evidence that IL-4 deficiency is associated with decreased formation of atherosclerotic lesions [<xref ref-type="bibr" rid="r30">30</xref>,<xref ref-type="bibr" rid="r31">31</xref>]. IL-4 promotes fibrinolysis by stimulating monocytes to produce t-PA [<xref ref-type="bibr" rid="r32">32</xref>]. A functional IL-4 polymorphism, which is characterized by a C to T substitution in the promoter region of the <italic>IL4</italic> gene (<italic>IL4</italic> &#x02212;584C&#x0003e;T, rs2243250), has been identified; thus far, it not been studied among BRVO patients [<xref ref-type="bibr" rid="r33">33</xref>].</p><p>IL-6 is a pleiotropic, pro-inflammatory cytokine, which is synthesized by monocytes and vascular endothelial cells [<xref ref-type="bibr" rid="r34">34</xref>]. It has been shown to contribute to atherogenesis by induction of endothelial dysfunction and enhancement of the expression of adhesion molecules [<xref ref-type="bibr" rid="r35">35</xref>]. In animal experiments, IL-6 has been observed to promote the development of early atherosclerotic lesions, thus strongly confirming an essential role of IL-6 in atherogenesis [<xref ref-type="bibr" rid="r10">10</xref>]. Furthermore, IL-6 promotes coagulation by upregulating the transcription of tissue factor, fibrinogen, and factor VIII [<xref ref-type="bibr" rid="r36">36</xref>-<xref ref-type="bibr" rid="r38">38</xref>]. Interestingly, IL-6 plasma levels have been reported as a risk determinant for venous thrombosis [<xref ref-type="bibr" rid="r39">39</xref>]. In 1998, Fishman and coworkers identified a functional gene polymorphism in the promoter region of the <italic>IL6</italic> gene, which is characterized by a C to T substitution at position &#x02212;174 (<italic>IL6</italic>&#x02212;174G&#x0003e;C, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800795">rs1800795</ext-link>). Using transfected HeLa cells, Fishman and colleagues found higher baseline IL-6 levels in cells with the G construct compared to those transfected with the C allele. Stimulation with LPS or IL-1 resulted in a significantly increased IL-6 transcription rate among cells carrying the G allele [<xref ref-type="bibr" rid="r40">40</xref>]. Another study using anti CD3/CD28-stimulated peripheral blood lymphocytes found three times higher IL-6 concentrations among carriers of the G allele [<xref ref-type="bibr" rid="r41">41</xref>]. Interestingly, the <italic>IL6</italic>&#x02212;174G&#x0003e;C polymorphism has previously been suggested to affect susceptibility to retinal artery occlusion (RAO). Its role in BRVO, however, still remains elusive [<xref ref-type="bibr" rid="r42">42</xref>].</p><p>In contrast to IL-6, interleukin 10 (IL-10) is an anti-inflammatory T<sub>H</sub>2-associated cytokine that mediates anti-atherogenic pathways by suppressing the synthesis of several pro-inflammatory cytokines such as IL-1&#x003b2;, IL-6, interleukin 12 (IL-12), TFN-&#x003b1;, and interferon-gamma (IFN-&#x003b3;) [<xref ref-type="bibr" rid="r43">43</xref>]. Its protective role in atherogenesis has also been confirmed by animal experiments [<xref ref-type="bibr" rid="r12">12</xref>]. As for hemostasis, IL-10 has been shown to inhibit LPS induced tissue factor expression in monocytes [<xref ref-type="bibr" rid="r44">44</xref>]. Gene polymorphisms are thought to account for up to 75% of the variability of IL-10 production [<xref ref-type="bibr" rid="r45">45</xref>], and increased IL-10 expression has been associated with the presence of a TCATA haplotype formed by polymorphisms at position &#x02212;3575, &#x02212;2763, &#x02212;1082, &#x02212;819, and &#x02212;592 in the promoter region of the <italic>IL10</italic> gene [<xref ref-type="bibr" rid="r46">46</xref>,<xref ref-type="bibr" rid="r47">47</xref>]. Due to strong linkage disequilibrium, the presence of this haplotype can be fully determined by analysis of the <italic>IL10</italic>&#x02212;592C&#x0003e;A polymorphism (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1800872">rs1800872</ext-link>). The <italic>IL10</italic>&#x02212;592A allele indicates the presence of the presumed anti-inflammatory TCATA haplotype, while the &#x02212;592C allele indicates its absence. As for retinal vascular diseases, an association between the <italic>IL10</italic>&#x02212;592C&#x0003e;A polymorphism and RAO risk has been reported [<xref ref-type="bibr" rid="r48">48</xref>].</p><p>Animal models have also provided evidence that the pro-inflammatory cytokine interleukin 18 (IL-18) contributes to the development of atherosclerosis. In synergy with IL-12, IL-18 promotes the T<sub>H</sub>1 immune response by inducing the IFN-&#x003b3; synthesis [<xref ref-type="bibr" rid="r19">19</xref>]. It also upregulates the synthesis of pro-inflammatory cytokines such as IL-1&#x003b2; and IL-8 as well as the expression of adhesion molecules [<xref ref-type="bibr" rid="r49">49</xref>]. In apoE knockout mice, administration of IL-18 has been associated with enhancement of atherosclerosis, whereas deficiency of IL-18 has been shown to reduce the extent of atherosclerosis [<xref ref-type="bibr" rid="r50">50</xref>,<xref ref-type="bibr" rid="r51">51</xref>]. IL-18 expression has been found to be decreased among carriers of the GCAGT haplotype formed by polymorphisms at position &#x02212;887, &#x02212;105, +105, +183, and +533 in the promoter and 5&#x02032;untranslated region of the <italic>IL18</italic> gene [<xref ref-type="bibr" rid="r52">52</xref>]. By analysis of the <italic>IL18</italic>+183A&#x0003e;G polymorphism (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5744292">rs5744292</ext-link>) the GCAGT haplotype can be identified, since this haplotype is the only one including the +183G allele. Thus, the <italic>IL18</italic>+183G allele indicates the presence of this haplotype, while the +183A allele indicates its absence.</p><p>Overexpression of TNF-&#x003b1;, a potent pro-inflammatory cytokine mainly produced by macrophages and T cells, has also been implicated in the pathogenesis of atherosclerosis [<xref ref-type="bibr" rid="r19">19</xref>]. TNF-&#x003b1; upregulates both the expression of adhesion molecules (ICAM-1, VCAM-1) and chemokines such as MCP-1, thereby facilitating the recruitment of monocytes to atherosclerotic lesions [<xref ref-type="bibr" rid="r53">53</xref>]. In apoE-deficient mice a lack of TNF-&#x003b1; was observed to be associated with a reduced size of atherosclerotic lesions [<xref ref-type="bibr" rid="r54">54</xref>]. TNF-&#x003b1; also exerts procoagulatory effects by upregulating tissue factor expression and by inhibition of the thrombomodulin/protein C anticoagulation pathway [<xref ref-type="bibr" rid="r14">14</xref>,<xref ref-type="bibr" rid="r15">15</xref>]. In addition, impairment of fibrinolysis is caused by TNF-&#x003b1; induced t-PA downregulation [<xref ref-type="bibr" rid="r55">55</xref>].</p><p>A <italic>TNF</italic> promoter polymorphism, which is caused by a G to A substitution at position &#x02212;308 of the <italic>TNF</italic> gene (<italic>TNF</italic>-308G&#x0003e;A, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800629">rs1800629</ext-link>), has been reported to modulate the expression of TNF-&#x003b1;. The presence of the <italic>TNF</italic>-308A allele has been found to be associated with higher constitutive and inducible TNF-&#x003b1; levels after LPS stimulation compared to the &#x02212;308GG genotype [<xref ref-type="bibr" rid="r56">56</xref>].</p><p>Importantly, the migration of leukocytes to the site of inflammation occurs along a gradient of various chemokines including MCP-1, IL-8, and RANTES (regulated on activation, normal T cell expressed and secreted). MCP-1 belongs to the CC family of chemokines, and its expression in both endothelial cells and monocytes can be induced by pro-inflammatory cytokines such as IL-1, IFN-&#x003b3;, and TNF-&#x003b1; [<xref ref-type="bibr" rid="r57">57</xref>]. A large body of evidence indicates that MCP-1 plays an essential role in atherogenesis by recruiting monocytes and macrophages to atherosclerotic lesions [<xref ref-type="bibr" rid="r58">58</xref>,<xref ref-type="bibr" rid="r59">59</xref>]. MCP-1 has also been reported to have a procoagulant function by inducing tissue factor expression [<xref ref-type="bibr" rid="r60">60</xref>]. An A to G substitution at position &#x02212;2518 of the MCP-1 gene (<italic>CCL2</italic>&#x02212;2518A&#x0003e;G, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1024611">rs1024611</ext-link>) has been noted to affect MCP-1 expression [<xref ref-type="bibr" rid="r61">61</xref>]. After IL-1&#x003b2; stimulation, peripheral blood mononuclear cells from individuals carrying the &#x02212;2518G allele showed a significantly higher MCP-1 synthesis than cells from individuals homozygous for the &#x02212;2518A allele [<xref ref-type="bibr" rid="r61">61</xref>].</p><p>Endothelial secretion of IL-8, a member of the CXC chemokine family, is induced by pro-inflammatory cytokines such as IL-1 and TNF-&#x003b1; [<xref ref-type="bibr" rid="r62">62</xref>]. IL-8 is a potent chemoattractant for neutrophils, and, like MCP-1, also triggers firm adhesion of rolling monocytes to the vascular endothelium, thus contributing to the development of atherosclerotic lesions [<xref ref-type="bibr" rid="r63">63</xref>]. Decreased susceptibility to atherosclerosis has been demonstrated in mice lacking the IL-8 receptor [<xref ref-type="bibr" rid="r64">64</xref>]. IL-8 has also been shown to increase the expression of tissue factor in monocytes [<xref ref-type="bibr" rid="r13">13</xref>]. Hull and coworkers [<xref ref-type="bibr" rid="r65">65</xref>] identified a common SNP in the promoter region of the <italic>IL8</italic> gene, which is caused by an A to T substitution at position &#x02212;251 (<italic>IL8</italic>&#x02212;251A&#x0003e;T, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4073">rs4073</ext-link>). The <italic>IL8</italic>&#x02212;251T allele was found to be associated with a two- to fivefold stronger luciferase expression than the &#x02212;251A allele, suggesting a pro-inflammatory effect in carriers of this allele [<xref ref-type="bibr" rid="r66">66</xref>].</p><p>Finally, RANTES, a member of the CC family of chemokines, is produced by T lymphocytes and monocytes. As a potent chemoattractant, RANTES has been shown to trigger monocyte arrest on dysfunctional endothelium [<xref ref-type="bibr" rid="r67">67</xref>]. Furthermore, RANTES is expressed by T cells in advanced atherosclerotic lesions [<xref ref-type="bibr" rid="r68">68</xref>]. In a hypercholesterolemic mouse model, administration of the CC chemokine antagonist Met-RANTES resulted in reduced atherosclerotic lesion sizes [<xref ref-type="bibr" rid="r69">69</xref>]. A SNP in the promoter region of the RANTES gene (<italic>CCL5</italic>), which is caused by a G to A substitution at position &#x02212;403 (<italic>CCL5</italic>&#x02212;403G&#x0003e;A, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2107538">rs2107538</ext-link>) has been identified [<xref ref-type="bibr" rid="r70">70</xref>]. In cells transfected with the &#x02212;403A variant, increased transcriptional activity has been demonstrated.</p><p>So far none of these functional gene polymorphisms has been studied as a potential risk factor for BRVO. The purpose of the present study was thus to investigate a hypothesized association between the aforementioned gene polymorphisms and the presence of BRVO.</p></sec><sec sec-type="methods"><title>Methods</title><p>The present study enrolled 398 patients with BRVO (228 females and 170 males) and 355 control subjects (206 females and 149 males). The mean age of patients was 67.1&#x000b1;11.0 years (range: 37&#x02013;93 years) and 68.3&#x000b1;13.8 years (range: 21&#x02013;93 years) in the control group. All participants were of Caucasian origin, living in the same geographical area and were seen at the local Department of Ophthalmology, Medical University of Graz. The study was approved by the Institutional Review Board of the Medical University of Graz and followed the principles of the Declaration of Helsinki. Prior to enrollment, written informed consent was obtained from all participants. Diagnosis of BRVO was made if fundus examination revealed venous dilation and tortuosity with intraretinal hemorrhages in a wedge-shaped region, with the apex of the wedge pointing to an arteriovenous crossing point.</p><p>The control group was hospital-based and comprised patients seen at the Department of Ophthalmology, Medical University of Graz for reasons other than retinal vascular occlusion, such as cataract or glaucoma surgery. All controls underwent a detailed fundus examination. Excluded as controls were patients who had a history of retinal vascular occlusions, deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke.</p><p>Arterial hypertension was defined by a systolic blood pressure &#x02265;140&#x000a0;mmHg, a diastolic blood pressure of &#x02265;90&#x000a0;mmHg, or the intake of antihypertensive drugs. Participants were classified as diabetics if they were being treated for insulin or non-insulin-dependent diabetes mellitus. Hypercholesterolemia was defined by fasting plasma cholesterol levels above 200&#x000a0;mg/dl or the intake of lipid-lowering drugs. Participants were classified as either ever (current/previous) smokers or nonsmokers. A standardized questionnaire was employed to obtain data on medication intake as well as history of deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.</p><p>Candidate gene polymorphisms were selected using the following criteria: association of the polymorphism with gene expression or activity of the gene product; involvement of the gene product in pro- or anti-inflammatory pathways; a minor allele frequency of 5% or higher; and no data available on the role of this gene variant in BRVO. Genomic DNA was isolated from whole blood by standard methods (QIA-AMP DNA, blood mini kit, Qiagen, Vienna, Austria) and stored at &#x02212;20&#x000a0;&#x000b0;C. Genotypes of the aforedescribed polymorphisms were determined by 5&#x02032; exonuclease assays (TaqMan). Applied Biosystems Assay-by-Design custom service (Applied Biosystems, Vienna, Austria) was used for design and manufacture of primer and probe sets. Sequences of primers and probes are presented in <xref ref-type="table" rid="t1">Table 1</xref>. Endpoint fluorescence data were exported into Excel format and analyzed as scatter plots. Samples were analyzed in batches, each containing 94 samples and 2 negative controls (water instead of DNA). Next, 50 samples were reanalyzed, and the results were identical for all samples.</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>Sequences of primers and probes for TaqMan genotyping assays.</title></caption><table frame="hsides" rules="groups"><col width="162" span="1"/><col width="104" span="1"/><col width="272" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Polymorphism</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Primer/probe</bold></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Sequence</bold></th></tr></thead><tbody><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL1B -</italic>511C&#x0003e;T (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=16944">rs16944</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">forward primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAGGCTCCTGCAATTGACAGA<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">reverse primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">TCTCTACCTTGGGTGCTGTTCT<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">C probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">VIC-CTGCCTCGGGAGCT-NFQ<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">T probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">FAM-CTGCCTCAGGAGCT-NFQ<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL1RN</italic> 1018T&#x0003e;C (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4251961">rs4251961</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">forward primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCGGTGAGCCCTAAGTCTAAGATAG<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">reverse primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCCCTTCAGACCTCATTTTGACA<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">T probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">VIC-AAAATGGACCTGATGCTAT-NFQ<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">C probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">FAM-AATGGACCTGGTGCTAT-NFQ<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL4</italic> -584C&#x0003e;T (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2243350">rs2243350</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">forward primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GACCTGTCCTTCTCAAAACACCTAA<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">reverse primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGCAGAATAACAGGCAGACTCT<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">C probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">VIC-CATTGTCCCCCAGTGCT-NFQ<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">T probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">FAM-CATTGTTCCCCAGTGCT-NFQ<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL6</italic> -174G&#x0003e;C (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800795">rs1800795</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">forward primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GACGACCTAAGCTGCACTTTTC<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">reverse primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGGCTGATTGGAAACCTTATTAAGATTG<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">G probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">VIC-CCTTTAGCATCGCAAGAC-NFQ<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">C probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">FAM-CTTTAGCATGGCAAGAC-NFQ<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL10</italic> -592C&#x0003e;A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800872">rs1800872</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">forward primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGTAAAGGAGCCTGGAACACATC<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">reverse primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GCCCTTCCATTTTACTTTCCAGAGA<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">C probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">VIC-CCCGCCTGTCCTGTAG-NFQ<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">A probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">FAM-CCGCCTGTACTGTAG-NFQ<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL18</italic> +183A&#x0003e;G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5744292">rs5744292</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">forward primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">AGCTGAGTGTAGTGACGCATG<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">reverse primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CTCCTGCCTCAGCCTCTTG<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">A probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">VIC-CCTCAATCCCAGCTACT-NFQ<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">G probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">FAM-CTCAATCCCGGCTACT-NFQ<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>TNF</italic> -308G&#x0003e;A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800629">rs1800629</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">forward primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">CCAAAAGAAATGGAGGCAATAGGTT<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">reverse primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGACCCTGGAGGCTGAAC<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">G probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">VIC-CCCGTCCCCATGCC-NFQ<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">A probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">FAM-CCCGTCCTCATGCC-NFQ<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>CCL2</italic> -2518A&#x0003e;G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1024611">rs1024611</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">forward primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGAGGGCATCTTTTCTTGACAGA<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">reverse primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GGAAGGTGAAGGGTATGAATCAGAA<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">A probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">VIC-CAGACAGCTATCACTTT-NFQ<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">G probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">FAM-AGACAGCTGTCACTTT-NFQ<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>IL8</italic> -251A&#x0003e;T (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4073">rs4073</ext-link>)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Assay-on-demand (C__11748116_10)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Predesigned assay from Applied Biosystems; primer and probe sequences not available.<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>CCL5</italic> -403G&#x0003e;A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2107538">rs2107538</ext-link>)</td><td valign="top" align="left" rowspan="1" colspan="1">forward primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">ACTGAGTCTTCAAAGTTCCTGCTT<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">reverse primer<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">GAGGACCCTCCTCAATAAAACACTTTATAAAT<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">G probe<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">VIC-CATTACAGATCTTACCTCCTTT-NFQ<hr/></td></tr><tr><td valign="top" colspan="1" align="left" scope="row" rowspan="1">A probe</td><td valign="top" align="left" rowspan="1" colspan="1">FAM-CATTACAGATCTTATCTCCTTT-NFQ</td></tr></tbody></table><table-wrap-foot><p>Sequences of primers and probes for TaqMan genotyping assays are presented. FAM and VIC are names of fluorescent dyes. NFQ is the abbreviation for non-fluorescent quencher.</p></table-wrap-foot></table-wrap><sec><title>Statistics</title><p>SPSS for windows (release 15.0.1; SPSS, Inc., Chicago, IL) was used for statistical analyses. Continuous variables were analyzed by Student&#x02019;s <italic>t</italic>-test and presented as means&#x000b1;SD. Categorial variables were presented as percentages and were compared by the &#x003c7;<sup>2</sup> test. Odds ratios and 95% confidence intervals (CI) were calculated by logistic regression analysis, and genotypes were coded assuming an allele dose effect (wildtype genotype=0, heterozygous carrier of the mutated allele=1, homozygous carrier for the mutated allele=2). A p&#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Clinical characteristics of both groups are shown in <xref ref-type="table" rid="t2">Table 2</xref>. Arterial hypertension was significantly more prevalent in BRVO patients than among control subjects (76.9% versus 51.5%; p&#x0003c;0.001). Hypercholesterolemia and ever-smoking status were also higher among patients than in the control group; however neither characteristics were statistically significant (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>Demographic data of patients with branch retinal vein occlusion and control subjects.</title></caption><table frame="hsides" rules="groups"><col width="126" span="1"/><col width="108" span="1"/><col width="108" span="1"/><col width="108" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Clinical characteristics</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>BRVO patients (n=398)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Control subjects (n=355)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p-value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Females<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">228 (57.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">206 (58.0%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.84<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mean age (years&#x000b1;SD)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67.1&#x000b1;11.0<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">68.3&#x000b1;13.8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.18<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Arterial hypertension<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">306 (76.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">183 (51.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Diabetes mellitus<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27 (6.8%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24 (6.8%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.99<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hypercholesterolemia<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">310 (77.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">260 (73.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.14<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ever-smoker</td><td valign="top" align="center" rowspan="1" colspan="1">119 (29.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">90 (25.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.16</td></tr></tbody></table><table-wrap-foot><p>Prevalence of arterial hypertension was significantly higher in branch retinal vein occlusion (BRVO) patients compared to control subjects. Data are mean&#x000b1;standard deviation, or number of subjects (%).</p></table-wrap-foot></table-wrap><p><xref ref-type="table" rid="t3">Table 3</xref> presents genotype distributions and allele frequencies in BRVO patients and controls. Neither allele frequencies nor genotype distributions of any of the investigated gene polymorphisms were found to be significantly different between patients and controls. Observed genotype distributions were in line with those predicted by the Hardy&#x02013;Weinberg equilibrium, and allele frequencies among controls were similar to those previously observed among other Caucasian populations [<xref ref-type="bibr" rid="r22">22</xref>,<xref ref-type="bibr" rid="r25">25</xref>,<xref ref-type="bibr" rid="r52">52</xref>,<xref ref-type="bibr" rid="r71">71</xref>-<xref ref-type="bibr" rid="r77">77</xref>]. In a logistic regression analysis, presence of BRVO was predicted by arterial hypertension, but not by any of the ten investigated gene polymorphisms (<xref ref-type="table" rid="t4">Table 4</xref>).</p><table-wrap id="t3" position="float"><label>Table 3</label><caption><title>Genotype and allele frequencies in patients with branch retinal vein occlusion and control subjects.</title></caption><table frame="hsides" rules="groups"><col width="166" span="1"/><col width="112" span="1"/><col width="88" span="1"/><col width="88" span="1"/><col width="88" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Polymorphism</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Genotype</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>BRVO patients</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Control subjects</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p-value</bold></th></tr></thead><tbody><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL1B</italic> -511C&#x0003e;T (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=16944">rs16944</ext-link>)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">183 (46.0%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">162 (45.6%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.68<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">184 (46.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">159 (44.8%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31 (7.8%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">34 (9.6%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">T allele frequency<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.309<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.32<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.66<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL1RN</italic> 1018T&#x0003e;C (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4251961">rs4251961</ext-link>)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">140 (35.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">145 (40.8%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.15<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">210 (52.8%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">162 (45.6%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48 (12.1%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48 (13.5%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">C allele frequency<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.384<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.363<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.4<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL4</italic> -584C&#x0003e;T (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2243350">rs2243250</ext-link>)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">287 (72.1%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">253 (71.3%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.58<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">106 (26.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">94 (26.5%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (1.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8 (2.3%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">T allele frequency<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.146<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.155<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.62<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL6</italic> -174G&#x0003e;C (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800795">rs1800795</ext-link>)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">130 (32.7%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">115 (32.4%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.97<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">197 (49.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">174 (49.0%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">71 (17.8%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">66 (18.6%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">C allele frequency<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.426<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.431<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.84<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL10</italic> -592C&#x0003e;A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800872">rs1800872</ext-link>)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">216 (54.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">186 (52.4%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.14<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">161 (40.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">137 (38.6%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">21 (5.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">32 (9.0%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A allele frequency<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.255<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.283<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.22<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL18</italic> +183A&#x0003e;G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5744292">rs5744292</ext-link>)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">232 (58.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">204 (57.5%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.11<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">154 (38.7%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">129 (36.3%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (3.0%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22 (6.2%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G allele frequency<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.224<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.244<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.36<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>TNF</italic> -308G&#x0003e;A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1800629">rs1800629</ext-link>)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">277 (69.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">251 (70.7%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.95<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">115 (28.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">99 (27.9%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 (1.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (1.4%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A allele frequency<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.16<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.154<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.75<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>CCL2</italic> -2518A&#x0003e;G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1024611">rs1024611</ext-link>)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">225 (56.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">206 (58.0%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.48<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">147 (36.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">133 (37.5%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26 (6.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16 (4.5%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G allele frequency<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.25<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.232<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.43<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>IL8 </italic>-251A&#x0003e;T (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=4073">rs4073</ext-link>)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">76 (19.1%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">82 (23.1%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.23<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">215 (54.0%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">171 (48.2%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107 (26.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">102 (28.7%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">T allele frequency<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.539<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.528<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.68<hr/></td></tr><tr><td rowspan="4" valign="top" align="left" scope="row" colspan="1"><italic>CCL5</italic> -403G&#x0003e;A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2107538">rs2107538</ext-link>)</td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">272 (68.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">235 (66.2%)<hr/></td><td rowspan="3" valign="top" align="center" colspan="1">0.63<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">113 (28.4%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">104 (29.3%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (3.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16 (4.5%)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A allele frequency</td><td valign="top" align="center" rowspan="1" colspan="1">0.175</td><td valign="top" align="center" rowspan="1" colspan="1">0.192</td><td valign="top" align="center" rowspan="1" colspan="1">0.4</td></tr></tbody></table><table-wrap-foot><p>Genotype and allele frequencies were not significantly different between branch retinal vein occlusion (BRVO) patients and control subjects, suggesting that these genotypes are not associated with BRVO risk.</p></table-wrap-foot></table-wrap><table-wrap id="t4" position="float"><label>Table 4</label><caption><title>Logistic regression analysis of branch retinal vein occlusion risk.</title></caption><table frame="hsides" rules="groups"><col width="105" span="1"/><col width="50" span="1"/><col width="92" span="1"/><col width="63" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Risk factor</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Odds ratio</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>95% Confidence Interval</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p-value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Arterial hypertension<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.33<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.42&#x02013;4.57<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>IL1B</italic> &#x02212;511T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.95<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.75&#x02013;1.20<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.67<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>IL1RN</italic> 1018C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.18<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.94&#x02013;1.49<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.15<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>IL4</italic> &#x02212;584T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.87<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.64&#x02013;1.18<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.37<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>IL6</italic> &#x02212;174C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.98<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.79&#x02013;1.22<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.87<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>IL10</italic> &#x02212;592A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.83<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.65&#x02013;1.05<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.12<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>IL18</italic> 183G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.89<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.69&#x02013;1.16<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.39<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>TNF</italic> &#x02212;308A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.74&#x02013;1.36<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.98<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>CCL2</italic> &#x02212;2518G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.15<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.90&#x02013;1.48<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.27<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>IL8</italic> &#x02212;251T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.06<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.85&#x02013;1.31<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.61<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic>CCL5</italic> &#x02212;403A</td><td valign="top" align="center" rowspan="1" colspan="1">0.86</td><td valign="top" align="center" rowspan="1" colspan="1">0.66&#x02013;1.13</td><td valign="top" align="center" rowspan="1" colspan="1">0.28</td></tr></tbody></table><table-wrap-foot><p>Arterial hypertension, but none of the investigated gene polymorphisms, was significantly associated with branch retinal vein occlusion (BRVO) risk.</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>Increased rigidity of the retinal artery leading to compression of the underlying vein at an arteriovenous crossing site has strongly been implicated in the pathogenesis of BRVO [<xref ref-type="bibr" rid="r3">3</xref>]. We hypothesized that BRVO susceptibility might be conferred by functional gene polymorphisms that affected the expression of cytokines or chemokines, which themselves have all been shown to affect atherogenesis. In addition, some cytokines also exert procoagulatory effects and may thus affect BRVO risk by a second mechanism. To improve biologic plausibility gene polymorphisms were only selected as candidate risk factors when these polymorphisms had previously been associated with gene expression or activity of the gene product, and an essential role of the gene product in pro- or anti-inflammatory pathways had been known. Some of these polymorphisms have been associated with cardiovascular diseases, indicating that alterations in the genetics of the inflammatory system may modify the risk of these diseases [<xref ref-type="bibr" rid="r77">77</xref>-<xref ref-type="bibr" rid="r83">83</xref>].</p><p>Neither genotype distributions nor allele frequencies of the investigated gene polymorphisms differed significantly between BRVO patients and control subjects. The statistical power of the present study to detect a potential association between the investigated gene polymorphisms and BRVO was calculated for the polymorphism with the lowest minor allele frequency (<italic>IL4&#x02212;584C&#x0003e;T</italic>). For this polymorphism, the present study had a statistical power of 0.80 to detect an odds ratio of &#x02265;1.55, and a statistical power of 0.99 to detect an odds ratio of &#x02265;2.0 for carriers of the mutated allele. For all other polymorphisms, the statistical power was equal or higher than that of the <italic>IL4&#x02212;584C&#x0003e;T</italic> polymorphism. Thus, our results strongly suggest that none of these gene variants is likely a major risk factor for BRVO.</p><p>The expression of cytokines and chemokines is also affected by factors other than gene polymorphisms [<xref ref-type="bibr" rid="r26">26</xref>,<xref ref-type="bibr" rid="r49">49</xref>,<xref ref-type="bibr" rid="r57">57</xref>,<xref ref-type="bibr" rid="r62">62</xref>]. For example, the expression of MCP-1 can be induced by pro-inflammatory cytokines such as IL-1 and TFN-&#x003b1; [<xref ref-type="bibr" rid="r57">57</xref>]. Thus, our finding that the investigated gene polymorphisms were not associated with a significantly increased risk for BRVO does not necessarily argue against a role of these cytokines and chemokines in the pathogenesis of BRVO.</p><p>Large prospective studies are clearly warranted to elucidate whether altered plasma concentrations of both cytokines and chemokines are predictive for the development of BRVO. This, however, can only be achieved by conducting a prospective instead of a retrospective study. Yet, it is also possible that increased expression of inflammatory mediators may not be detected systemically in blood, but only locally in the vascular wall.</p><p>When interpreting the data of the present study, some limitations have to be considered. First, blood samples were obtained after the occurrence of BRVO. Thus, the present study is not suitable to investigate plasma cytokine and chemokine patterns. The aim of this study, however, was to investigate a hypothesized association between genetic variants and BRVO risk. As genotypes do not change during a person&#x02019;s lifetime, the aforementioned limitation does not apply to the analysis of gene polymorphisms. Second, gene variants have been shown to vary between populations of different ethnic origins. Thus, our findings may not necessarily apply to ethnicities other than Caucasian. Finally, genetic studies are designed to compare allele or genotype frequencies between case and control groups. A statistical difference in frequencies between cases and controls suggests that the investigated genetic variant is associated with the disease. In the present candidate gene approach, we selected genetic polymorphisms on the basis of prior knowledge of gene function and allele frequencies. Thus, the candidate gene approach has the advantage of a higher probability of true association, which has been recognized as an important factor influencing the outcome of association studies [<xref ref-type="bibr" rid="r84">84</xref>]. The main limitation of the candidate gene approach is the usually low number of polymorphisms investigated. Whole genome association studies, including hundreds of thousands of polymorphisms, are now available. It is likely that results of such studies will provide novel candidates for genetic susceptibility to BRVO.</p><p>In conclusion, as none of the investigated gene variants was significantly more prevalent in BRVO patients than among control subjects, our data suggest that these polymorphisms are unlikely major risk factors for BRVO in a Caucasian population.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by the Anniversary Fund of the Oesterreichische Nationalbank (Project-Nr. 12245). We thank Ms. Gabriele Trummer, Ms. Christa Wachswender, and Ms. Manuela Fischl for their excellent technical assistance.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frangieh</surname><given-names>GT</given-names></name><name><surname>Green</surname><given-names>RW</given-names></name><name><surname>Barraquer-Somers</surname><given-names>E</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name></person-group><article-title>Histopathologic study of nine branch retinal vein occlusions.</article-title><source>Arch Ophthalmol</source><year>1982</year><volume>100</volume><fpage>1132</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">6178389</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Sastry</surname><given-names>SM</given-names></name><name><surname>Sperduto</surname><given-names>RD</given-names></name><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Remaley</surname><given-names>NA</given-names></name></person-group><article-title>Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group.</article-title><source>Ophthalmology</source><year>1993</year><volume>100</volume><fpage>423</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8460014</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="book">Fekrat S, Finkelstein D. Venous occlusive disease. In: Regillo CD, Brown GC, Flynn HW Jr, editors. Vitreoretinal disease. The Essentials. New York, Stuttgart: Thieme; 1999. p. 117&#x02013;32.</citation></ref><ref id="r4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><collab>The Eye Disease Case-control Study Group</collab></person-group><article-title>Risk factors for branch retinal vein occlusion.</article-title><source>Am J Ophthalmol</source><year>1993</year><volume>116</volume><fpage>286</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">8357052</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Mahoney</surname><given-names>PR</given-names></name><name><surname>Wong</surname><given-names>DT</given-names></name><name><surname>Ray</surname><given-names>JG</given-names></name></person-group><article-title>Retinal vein occlusion and traditional risk factors for atherosclerosis.</article-title><source>Arch Ophthalmol</source><year>2008</year><volume>126</volume><fpage>692</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18474782</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>MC</given-names></name><name><surname>den Heijer</surname><given-names>M</given-names></name><name><surname>Cruysberg</surname><given-names>JR</given-names></name><name><surname>Wollersheim</surname><given-names>H</given-names></name><name><surname>Bredie</surname><given-names>SJ</given-names></name></person-group><article-title>Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors.</article-title><source>Thromb Haemost</source><year>2005</year><volume>93</volume><fpage>1021</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15968383</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cahill</surname><given-names>MT</given-names></name><name><surname>Stinnett</surname><given-names>SS</given-names></name><name><surname>Fekrat</surname><given-names>S</given-names></name></person-group><article-title>Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease.</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>136</volume><fpage>1136</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">14644226</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>R</given-names></name></person-group><article-title>Atherosclerosis &#x02013; an inflammatory disease.</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>115</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">9887164</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frostegard</surname><given-names>J</given-names></name><name><surname>Ulfgren</surname><given-names>AK</given-names></name><name><surname>Nyberg</surname><given-names>P</given-names></name><name><surname>Hedin</surname><given-names>U</given-names></name><name><surname>Swedenborg</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines.</article-title><source>Atherosclerosis</source><year>1999</year><volume>145</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">10428293</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>SA</given-names></name><name><surname>Sakkinen</surname><given-names>P</given-names></name><name><surname>Conze</surname><given-names>D</given-names></name><name><surname>Hardin</surname><given-names>N</given-names></name><name><surname>Tracy</surname><given-names>R</given-names></name></person-group><article-title>Interleukin-6 exacerbates early atherosclerosis in mice.</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1999</year><volume>19</volume><fpage>2364</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10521365</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitman</surname><given-names>SC</given-names></name><name><surname>Ravisankar</surname><given-names>P</given-names></name><name><surname>Elam</surname><given-names>H</given-names></name><name><surname>Daugherty</surname><given-names>A</given-names></name></person-group><article-title>Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E&#x02212;/&#x02212; mice.</article-title><source>Am J Pathol</source><year>2000</year><volume>157</volume><fpage>1819</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">11106554</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinderski</surname><given-names>LJ</given-names></name><name><surname>Fischbein</surname><given-names>MP</given-names></name><name><surname>Subbanagounder</surname><given-names>G</given-names></name><name><surname>Fishbein</surname><given-names>MC</given-names></name><name><surname>Kubo</surname><given-names>N</given-names></name><name><surname>Cheroutre</surname><given-names>H</given-names></name><name><surname>Curtiss</surname><given-names>LK</given-names></name><name><surname>Berliner</surname><given-names>JA</given-names></name><name><surname>Boisvert</surname><given-names>WA</given-names></name></person-group><article-title>Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor- deficient mice by altering lymphocyte and macrophage phenotypes.</article-title><source>Circ Res</source><year>2002</year><volume>90</volume><fpage>1064</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12039795</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grignani</surname><given-names>G</given-names></name><name><surname>Maiolo</surname><given-names>A</given-names></name></person-group><article-title>Cytokines and hemostasis.</article-title><source>Haematologica</source><year>2000</year><volume>85</volume><fpage>967</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">10980636</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Poll</surname><given-names>T</given-names></name><name><surname>B&#x000fc;ller</surname><given-names>HR</given-names></name><name><surname>ten Cate</surname><given-names>H</given-names></name><name><surname>Wortel</surname><given-names>CH</given-names></name><name><surname>Bauer</surname><given-names>KA</given-names></name><name><surname>van Deventer</surname><given-names>SJ</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Sauerwein</surname><given-names>HP</given-names></name><name><surname>Rosenberg</surname><given-names>RD</given-names></name><name><surname>ten Cate</surname><given-names>JW</given-names></name></person-group><article-title>Activation of coagulation after administration of tumor necrosis factor to normal subjects.</article-title><source>N Engl J Med</source><year>1990</year><volume>322</volume><fpage>1622</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2188129</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>EM</given-names></name><name><surname>Rosenberg</surname><given-names>RD</given-names></name></person-group><article-title>Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells.</article-title><source>Mol Cell Biol</source><year>1988</year><volume>8</volume><fpage>5588</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">2854203</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>EA</given-names></name><name><surname>Kahn</surname><given-names>SR</given-names></name></person-group><article-title>The relationship between inflammation and venous thrombosis. A systematic review of clinical studies.</article-title><source>Thromb Haemost</source><year>2005</year><volume>94</volume><fpage>362</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16113826</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stouthard</surname><given-names>JM</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>Hack</surname><given-names>CE</given-names></name><name><surname>Veenhof</surname><given-names>CH</given-names></name><name><surname>Romijn</surname><given-names>HA</given-names></name><name><surname>Sauerwein</surname><given-names>HP</given-names></name><name><surname>van der Poll</surname><given-names>T</given-names></name></person-group><article-title>Interleukin-6 stimulates coagulation, not fibrinolysis, in humans.</article-title><source>Thromb Haemost</source><year>1996</year><volume>76</volume><fpage>738</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">8950783</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>Biologic basis for interleukin-1 in disease.</article-title><source>Blood</source><year>1996</year><volume>87</volume><fpage>2095</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">8630372</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>JL</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Sch&#x000f6;nbeck</surname><given-names>U</given-names></name></person-group><article-title>Cytokines in the pathogenesis of atherosclerosis.</article-title><source>Thromb Haemost</source><year>2002</year><volume>88</volume><fpage>554</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">12362224</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirii</surname><given-names>H</given-names></name><name><surname>Niwa</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Asano</surname><given-names>M</given-names></name><name><surname>Moriwaki</surname><given-names>H</given-names></name><name><surname>Seishima</surname><given-names>M</given-names></name></person-group><article-title>Lack of interleukin-1 beta decreases the severity of atherosclerosis in ApoE-deficient mice.</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2003</year><volume>23</volume><fpage>656</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">12615675</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>M</given-names></name><name><surname>Masubuchi</surname><given-names>H</given-names></name><name><surname>Seki</surname><given-names>T</given-names></name><name><surname>Ariga</surname><given-names>T</given-names></name></person-group><article-title>IL-1&#x003b2; down-regulates tissue-type plasminogen activator by up-regulating low-density lipoprotein receptor-related protein in AML 12 cells.</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>288</volume><fpage>42</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11594749</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iacoviello</surname><given-names>L</given-names></name><name><surname>Di Castelnuovo</surname><given-names>A</given-names></name><name><surname>Gattone</surname><given-names>M</given-names></name><name><surname>Pezzini</surname><given-names>A</given-names></name><name><surname>Assanelli</surname><given-names>D</given-names></name><name><surname>Lorenzet</surname><given-names>R</given-names></name><name><surname>Del Zotto</surname><given-names>E</given-names></name><name><surname>Colombo</surname><given-names>M</given-names></name><name><surname>Napoleone</surname><given-names>E</given-names></name><name><surname>Amore</surname><given-names>C</given-names></name><name><surname>D&#x02019;Orazio</surname><given-names>A</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name><name><surname>de Gaetano</surname><given-names>G</given-names></name><name><surname>Giannuzzi</surname><given-names>P</given-names></name><name><surname>Donati</surname><given-names>MB</given-names></name></person-group><article-title>IGIGI Investigators. Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro.</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2005</year><volume>25</volume><fpage>222</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15539626</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devlin</surname><given-names>CM</given-names></name><name><surname>Kuriakose</surname><given-names>G</given-names></name><name><surname>Hirsch</surname><given-names>E</given-names></name><name><surname>Tabas</surname><given-names>I</given-names></name></person-group><article-title>Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size.</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>6280</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11983917</pub-id></citation></ref><ref id="r24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isoda</surname><given-names>K</given-names></name><name><surname>Sawada</surname><given-names>S</given-names></name><name><surname>Ishigami</surname><given-names>N</given-names></name><name><surname>Matsuki</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><name><surname>Kusuhara</surname><given-names>M</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name><name><surname>Ohsuzu</surname><given-names>F</given-names></name></person-group><article-title>Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice.</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2004</year><volume>24</volume><fpage>1068</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15059807</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Wurfel</surname><given-names>MM</given-names></name><name><surname>Lange</surname><given-names>LA</given-names></name><name><surname>Carlson</surname><given-names>CS</given-names></name><name><surname>Nord</surname><given-names>AS</given-names></name><name><surname>Carty</surname><given-names>CL</given-names></name><name><surname>Rieder</surname><given-names>MJ</given-names></name><name><surname>Desmarais</surname><given-names>C</given-names></name><name><surname>Jenny</surname><given-names>NS</given-names></name><name><surname>Iribarren</surname><given-names>C</given-names></name><name><surname>Walston</surname><given-names>JD</given-names></name><name><surname>Williams</surname><given-names>OD</given-names></name><name><surname>Nickerson</surname><given-names>DA</given-names></name><name><surname>Jarvik</surname><given-names>GP</given-names></name></person-group><article-title>Polymorphisms of the IL-1 receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation.</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2008</year><volume>28</volume><fpage>1407</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18451331</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iademarco</surname><given-names>MF</given-names></name><name><surname>Barks</surname><given-names>JL</given-names></name><name><surname>Dean</surname><given-names>DC</given-names></name></person-group><article-title>Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells.</article-title><source>J Clin Invest</source><year>1995</year><volume>95</volume><fpage>264</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">7529260</pub-id></citation></ref><ref id="r27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barks</surname><given-names>JL</given-names></name><name><surname>McQuillan</surname><given-names>JJ</given-names></name><name><surname>Iademarco</surname><given-names>MF</given-names></name></person-group><article-title>TNF-alpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells.</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><fpage>4532</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9379054</pub-id></citation></ref><ref id="r28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>DJ</given-names></name><name><surname>Kuhn</surname><given-names>H</given-names></name><name><surname>Mulkins</surname><given-names>M</given-names></name><name><surname>Highland</surname><given-names>E</given-names></name><name><surname>Sigal</surname><given-names>E</given-names></name></person-group><article-title>Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase.</article-title><source>Proc Natl Acad Sci USA</source><year>1992</year><volume>89</volume><fpage>217</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">1729692</pub-id></citation></ref><ref id="r29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walch</surname><given-names>L</given-names></name><name><surname>Massade</surname><given-names>L</given-names></name><name><surname>Dufilho</surname><given-names>M</given-names></name><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>Rendu</surname><given-names>F</given-names></name></person-group><article-title>Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression.</article-title><source>Atherosclerosis</source><year>2006</year><volume>187</volume><fpage>285</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16249002</pub-id></citation></ref><ref id="r30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>P</given-names></name><name><surname>Tipping</surname><given-names>PG</given-names></name></person-group><article-title>The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice.</article-title><source>Am J Pathol</source><year>2003</year><volume>163</volume><fpage>1117</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">12937153</pub-id></citation></ref><ref id="r31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>VL</given-names></name><name><surname>Szilvassy</surname><given-names>SJ</given-names></name><name><surname>Daugherty</surname><given-names>A</given-names></name></person-group><article-title>Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor &#x02212;/&#x02212; mice.</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2002</year><volume>22</volume><fpage>456</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11884290</pub-id></citation></ref><ref id="r32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>PH</given-names></name><name><surname>Burgess</surname><given-names>DR</given-names></name><name><surname>Vitti</surname><given-names>GF</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name></person-group><article-title>Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator.</article-title><source>Blood</source><year>1989</year><volume>74</volume><fpage>1222</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2504304</pub-id></citation></ref><ref id="r33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenwasser</surname><given-names>LJ</given-names></name><name><surname>Borish</surname><given-names>L</given-names></name></person-group><article-title>Promoter polymorphisms predisposing to the development of asthma and atopy.</article-title><source>Clin Exp Allergy</source><year>1998</year><volume>28</volume><issue>Suppl 5</issue><fpage>13</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9988441</pub-id></citation></ref><ref id="r34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Snick</surname><given-names>J</given-names></name></person-group><article-title>Interleukin-6: an overview.</article-title><source>Annu Rev Immunol</source><year>1990</year><volume>8</volume><fpage>253</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">2188664</pub-id></citation></ref><ref id="r35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Sironi</surname><given-names>M</given-names></name><name><surname>Toniatti</surname><given-names>C</given-names></name><name><surname>Polentarutti</surname><given-names>N</given-names></name><name><surname>Fruscella</surname><given-names>P</given-names></name><name><surname>Ghezzi</surname><given-names>P</given-names></name><name><surname>Faggioni</surname><given-names>R</given-names></name><name><surname>Luini</surname><given-names>W</given-names></name><name><surname>van Hinsbergh</surname><given-names>V</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name><name><surname>Bussolino</surname><given-names>F</given-names></name><name><surname>Poli</surname><given-names>V</given-names></name><name><surname>Ciliberto</surname><given-names>G</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.</article-title><source>Immunity</source><year>1997</year><volume>6</volume><fpage>315</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">9075932</pub-id></citation></ref><ref id="r36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>FJ</given-names></name><name><surname>Ott</surname><given-names>I</given-names></name><name><surname>Marx</surname><given-names>N</given-names></name><name><surname>Luther</surname><given-names>T</given-names></name><name><surname>Kenngott</surname><given-names>S</given-names></name><name><surname>Gawaz</surname><given-names>M</given-names></name><name><surname>Kotzsch</surname><given-names>M</given-names></name><name><surname>Sch&#x000f6;mig</surname><given-names>A</given-names></name></person-group><article-title>Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity.</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1997</year><volume>17</volume><fpage>3399</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">9437185</pub-id></citation></ref><ref id="r37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amrani</surname><given-names>DL</given-names></name></person-group><article-title>Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control.</article-title><source>Blood Coagul Fibrinolysis</source><year>1990</year><volume>1</volume><fpage>443</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2133221</pub-id></citation></ref><ref id="r38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stirling</surname><given-names>D</given-names></name><name><surname>Hannant</surname><given-names>WA</given-names></name><name><surname>Ludlam</surname><given-names>CA</given-names></name></person-group><article-title>Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6.</article-title><source>Thromb Haemost</source><year>1998</year><volume>79</volume><fpage>74</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9459327</pub-id></citation></ref><ref id="r39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reitsma</surname><given-names>PH</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name></person-group><article-title>Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study.</article-title><source>J Thromb Haemost</source><year>2004</year><volume>2</volume><fpage>619</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">15102017</pub-id></citation></ref><ref id="r40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fishman</surname><given-names>D</given-names></name><name><surname>Faulds</surname><given-names>G</given-names></name><name><surname>Jeffery</surname><given-names>R</given-names></name><name><surname>Mohamed-Ali</surname><given-names>V</given-names></name><name><surname>Yudkin</surname><given-names>JS</given-names></name><name><surname>Humphries</surname><given-names>S</given-names></name><name><surname>Woo</surname><given-names>P</given-names></name></person-group><article-title>The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.</article-title><source>J Clin Invest</source><year>1998</year><volume>102</volume><fpage>1369</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">9769329</pub-id></citation></ref><ref id="r41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>SC</given-names></name><name><surname>Stanley</surname><given-names>EM</given-names></name><name><surname>Darrin Cox</surname><given-names>E</given-names></name><name><surname>Craighead</surname><given-names>N</given-names></name><name><surname>DiMercurio</surname><given-names>BS</given-names></name><name><surname>Koziol</surname><given-names>DE</given-names></name><name><surname>Harlan</surname><given-names>DM</given-names></name><name><surname>Kirk</surname><given-names>AD</given-names></name><name><surname>Blair</surname><given-names>BJ</given-names></name></person-group><article-title>Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28 stimulated peripheral blood lymphocytes.</article-title><source>Transplantation</source><year>2001</year><volume>72</volume><fpage>1444</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11685118</pub-id></citation></ref><ref id="r42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weger</surname><given-names>M</given-names></name><name><surname>Steinbrugger</surname><given-names>I</given-names></name><name><surname>Haas</surname><given-names>A</given-names></name><name><surname>M&#x000e4;rz</surname><given-names>W</given-names></name><name><surname>El-Shabrawi</surname><given-names>Y</given-names></name><name><surname>Weger</surname><given-names>W</given-names></name><name><surname>Schmut</surname><given-names>O</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name></person-group><article-title>Role of the interleukin-6 &#x02212;174G&#x0003e;C gene polymorphism in retinal artery occlusion.</article-title><source>Stroke</source><year>2005</year><volume>36</volume><fpage>249</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">15604420</pub-id></citation></ref><ref id="r43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fiorentino</surname><given-names>DF</given-names></name><name><surname>Zlotnik</surname><given-names>A</given-names></name><name><surname>Vieria</surname><given-names>P</given-names></name><name><surname>Mosmann</surname><given-names>TR</given-names></name><name><surname>Howard</surname><given-names>M</given-names></name><name><surname>Moore</surname><given-names>KW</given-names></name><name><surname>O&#x02019;Garra</surname><given-names>A</given-names></name></person-group><article-title>IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.</article-title><source>J Immunol</source><year>1991</year><volume>146</volume><fpage>3444</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">1827484</pub-id></citation></ref><ref id="r44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramani</surname><given-names>M</given-names></name><name><surname>Ollivier</surname><given-names>V</given-names></name><name><surname>Khechai</surname><given-names>F</given-names></name><name><surname>Vu</surname><given-names>T</given-names></name><name><surname>Ternisien</surname><given-names>C</given-names></name><name><surname>Bridey</surname><given-names>F</given-names></name><name><surname>de Prost</surname><given-names>D</given-names></name></person-group><article-title>Interleukin-10 inhibits endotoxin-induced tissue factor mRNA production by human monocytes.</article-title><source>FEBS Lett</source><year>1993</year><volume>334</volume><fpage>114</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8224211</pub-id></citation></ref><ref id="r45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Craen</surname><given-names>AJ</given-names></name><name><surname>Posthuma</surname><given-names>D</given-names></name><name><surname>Remarque</surname><given-names>EJ</given-names></name><name><surname>van den Biggelaar</surname><given-names>AH</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name></person-group><article-title>Heritability estimates of innate immunity: an extended twin study.</article-title><source>Genes Immun</source><year>2005</year><volume>6</volume><fpage>167</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">15674372</pub-id></citation></ref><ref id="r46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>AW</given-names></name><name><surname>Edberg</surname><given-names>JC</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name><name><surname>Kimberly</surname><given-names>RP</given-names></name></person-group><article-title>Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus.</article-title><source>J Immunol</source><year>2001</year><volume>166</volume><fpage>3915</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">11238636</pub-id></citation></ref><ref id="r47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Storer</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>PJ</given-names></name><name><surname>Tseng</surname><given-names>LH</given-names></name><name><surname>Gooley</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Hansen</surname><given-names>JA</given-names></name></person-group><article-title>Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>2201</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">14657427</pub-id></citation></ref><ref id="r48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weger</surname><given-names>M</given-names></name><name><surname>Steinbrugger</surname><given-names>I</given-names></name><name><surname>El-Shabrawi</surname><given-names>Y</given-names></name><name><surname>Wegscheider</surname><given-names>BJ</given-names></name><name><surname>Weger</surname><given-names>W</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>Schmut</surname><given-names>O</given-names></name><name><surname>Haas</surname><given-names>A</given-names></name></person-group><article-title>Haplotype-tagging interleukin-10 promoter polymorphism is associated with reduced risk of retinal artery occlusion.</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>549</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">17438520</pub-id></citation></ref><ref id="r49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puren</surname><given-names>AJ</given-names></name><name><surname>Fantuzzi</surname><given-names>G</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>MS</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells.</article-title><source>J Clin Invest</source><year>1998</year><volume>101</volume><fpage>711</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">9449707</pub-id></citation></ref><ref id="r50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elhage</surname><given-names>R</given-names></name><name><surname>Jawien</surname><given-names>J</given-names></name><name><surname>Rudling</surname><given-names>M</given-names></name><name><surname>Ljunggren</surname><given-names>HG</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Bayard</surname><given-names>F</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group><article-title>Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice.</article-title><source>Cardiovasc Res</source><year>2003</year><volume>59</volume><fpage>234</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12829194</pub-id></citation></ref><ref id="r51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitman</surname><given-names>SC</given-names></name><name><surname>Ravisankar</surname><given-names>P</given-names></name><name><surname>Daugherty</surname><given-names>A</given-names></name></person-group><article-title>Interleukin-18 enhances atherosclerosis in apolipoprotein E(&#x02212;/&#x02212;) mice through release of interferon-gamma.</article-title><source>Circ Res</source><year>2002</year><volume>90</volume><fpage>E34</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11834721</pub-id></citation></ref><ref id="r52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tiret</surname><given-names>L</given-names></name><name><surname>Godefroy</surname><given-names>T</given-names></name><name><surname>Lubos</surname><given-names>E</given-names></name><name><surname>Nicaud</surname><given-names>V</given-names></name><name><surname>Tregouet</surname><given-names>DA</given-names></name><name><surname>Barbaux</surname><given-names>S</given-names></name><name><surname>Schnabel</surname><given-names>R</given-names></name><name><surname>Bickel</surname><given-names>C</given-names></name><name><surname>Espinola-Klein</surname><given-names>C</given-names></name><name><surname>Poirier</surname><given-names>O</given-names></name><name><surname>Perret</surname><given-names>C</given-names></name><name><surname>M&#x000fc;nzel</surname><given-names>T</given-names></name><name><surname>Rupprecht</surname><given-names>HJ</given-names></name><name><surname>Lackner</surname><given-names>K</given-names></name><name><surname>Cambien</surname><given-names>F</given-names></name><name><surname>Blankenberg</surname><given-names>S</given-names></name></person-group><article-title>AtheroGene Investigators. Genetic analysis of interleukin-18 system highlights the role of interleukin-18 gene in cardiovascular disease.</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>643</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">16043644</pub-id></citation></ref><ref id="r53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vassalli</surname><given-names>P</given-names></name></person-group><article-title>The pathophysiology of tumor necrosis factors.</article-title><source>Annu Rev Immunol</source><year>1992</year><volume>10</volume><fpage>411</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">1590993</pub-id></citation></ref><ref id="r54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>H</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Niwa</surname><given-names>T</given-names></name><name><surname>Kirii</surname><given-names>H</given-names></name><name><surname>Iwamoto</surname><given-names>N</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Sekikawa</surname><given-names>K</given-names></name><name><surname>Seishama</surname><given-names>M</given-names></name></person-group><article-title>Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice.</article-title><source>Atherosclerosis</source><year>2005</year><volume>180</volume><fpage>11</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15823270</pub-id></citation></ref><ref id="r55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ulfhammer</surname><given-names>E</given-names></name><name><surname>Larsson</surname><given-names>P</given-names></name><name><surname>Karlsson</surname><given-names>L</given-names></name><name><surname>Hrafnkelsdottir</surname><given-names>T</given-names></name><name><surname>Bokarewa</surname><given-names>M</given-names></name><name><surname>Tarkowski</surname><given-names>A</given-names></name><name><surname>Jern</surname><given-names>S</given-names></name></person-group><article-title>TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent.</article-title><source>J Thromb Haemost</source><year>2006</year><volume>4</volume><fpage>1781</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16879221</pub-id></citation></ref><ref id="r56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>E</given-names></name><name><surname>Franchimont</surname><given-names>D</given-names></name><name><surname>Piron</surname><given-names>A</given-names></name><name><surname>Gevaert</surname><given-names>Y</given-names></name><name><surname>Schaaf-Lafontaine</surname><given-names>N</given-names></name><name><surname>Roland</surname><given-names>S</given-names></name><name><surname>Mahieu</surname><given-names>P</given-names></name><name><surname>Malaise</surname><given-names>M</given-names></name><name><surname>De Groote</surname><given-names>D</given-names></name><name><surname>Louis</surname><given-names>R</given-names></name><name><surname>Belaiche</surname><given-names>J</given-names></name></person-group><article-title>Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans.</article-title><source>Clin Exp Immunol</source><year>1998</year><volume>113</volume><fpage>401</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9737669</pub-id></citation></ref><ref id="r57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Colotta</surname><given-names>F</given-names></name><name><surname>Dejana</surname><given-names>E</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Oppenheim</surname><given-names>JJ</given-names></name><name><surname>Larsen</surname><given-names>CG</given-names></name><name><surname>Zachariae</surname><given-names>CO</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name></person-group><article-title>Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor.</article-title><source>J Immunol</source><year>1990</year><volume>144</volume><fpage>3034</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2182712</pub-id></citation></ref><ref id="r58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boring</surname><given-names>L</given-names></name><name><surname>Gosling</surname><given-names>J</given-names></name><name><surname>Cleary</surname><given-names>M</given-names></name><name><surname>Charo</surname><given-names>IF</given-names></name></person-group><article-title>Decreased lesion formation in CCR2 &#x02212;/&#x02212; mice reveals a role for chemokines in the initiation of atherosclerosis.</article-title><source>Nature</source><year>1998</year><volume>394</volume><fpage>894</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9732872</pub-id></citation></ref><ref id="r59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>RJ</given-names></name><name><surname>Bourassa</surname><given-names>PA</given-names></name><name><surname>Lindsey</surname><given-names>S</given-names></name><name><surname>Weng</surname><given-names>W</given-names></name><name><surname>Natoli</surname><given-names>E</given-names></name><name><surname>Rollins</surname><given-names>BJ</given-names></name><name><surname>Milos</surname><given-names>PM</given-names></name></person-group><article-title>Monocyte chemoattractant protein-1 accelerates atherosclerosis in apoliopoprotein E-deficient mice.</article-title><source>Arterioscler Thromb Vasc Biol</source><year>1999</year><volume>19</volume><fpage>1518</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">10364084</pub-id></citation></ref><ref id="r60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schecter</surname><given-names>AD</given-names></name><name><surname>Rollins</surname><given-names>BJ</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Charo</surname><given-names>IF</given-names></name><name><surname>Fallon</surname><given-names>JT</given-names></name><name><surname>Rossikhina</surname><given-names>M</given-names></name><name><surname>Giesen</surname><given-names>PL</given-names></name><name><surname>Nemerson</surname><given-names>Y</given-names></name><name><surname>Taubman</surname><given-names>MB</given-names></name></person-group><article-title>Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells.</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>28568</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">9353321</pub-id></citation></ref><ref id="r61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rovin</surname><given-names>BH</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Saxena</surname><given-names>R</given-names></name></person-group><article-title>A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression.</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>259</volume><fpage>344</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10362511</pub-id></citation></ref><ref id="r62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplanski</surname><given-names>G</given-names></name><name><surname>Farnarier</surname><given-names>C</given-names></name><name><surname>Kaplanski</surname><given-names>S</given-names></name><name><surname>Porat</surname><given-names>R</given-names></name><name><surname>Shapiro</surname><given-names>L</given-names></name><name><surname>Bongrand</surname><given-names>P</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism.</article-title><source>Blood</source><year>1994</year><volume>84</volume><fpage>4242</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7994038</pub-id></citation></ref><ref id="r63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerszten</surname><given-names>RE</given-names></name><name><surname>Garcia-Zepeda</surname><given-names>EA</given-names></name><name><surname>Lim</surname><given-names>YC</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>HA</given-names></name><name><surname>Gimbrone</surname><given-names>MA</given-names><suffix>Jr</suffix></name><name><surname>Luster</surname><given-names>AD</given-names></name><name><surname>Luscinskas</surname><given-names>FW</given-names></name><name><surname>Rosenzweig</surname><given-names>A</given-names></name></person-group><article-title>MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions.</article-title><source>Nature</source><year>1999</year><volume>398</volume><fpage>718</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10227295</pub-id></citation></ref><ref id="r64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boisvert</surname><given-names>WA</given-names></name><name><surname>Santiago</surname><given-names>R</given-names></name><name><surname>Curtiss</surname><given-names>LK</given-names></name><name><surname>Terkeltaub</surname><given-names>RA</given-names></name></person-group><article-title>A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice.</article-title><source>J Clin Invest</source><year>1998</year><volume>101</volume><fpage>353</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">9435307</pub-id></citation></ref><ref id="r65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hull</surname><given-names>J</given-names></name><name><surname>Thomson</surname><given-names>A</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name></person-group><article-title>Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families.</article-title><source>Thorax</source><year>2000</year><volume>55</volume><fpage>1023</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11083887</pub-id></citation></ref><ref id="r66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WP</given-names></name><name><surname>Tai</surname><given-names>DI</given-names></name><name><surname>Lan</surname><given-names>KH</given-names></name><name><surname>Li</surname><given-names>AF</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name><name><surname>Lin</surname><given-names>EJ</given-names></name><name><surname>Lin</surname><given-names>YP</given-names></name><name><surname>Sheu</surname><given-names>ML</given-names></name><name><surname>Li</surname><given-names>CP</given-names></name><name><surname>Chang</surname><given-names>FY</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Yen</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>SD</given-names></name></person-group><article-title>The &#x02212;251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population.</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>6431</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16166417</pub-id></citation></ref><ref id="r67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Hundelshausen</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>KS</given-names></name><name><surname>Huo</surname><given-names>Y</given-names></name><name><surname>Proudfoot</surname><given-names>AE</given-names></name><name><surname>Nelson</surname><given-names>PJ</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name></person-group><article-title>RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium.</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>1772</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11282909</pub-id></citation></ref><ref id="r68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilcox</surname><given-names>JN</given-names></name><name><surname>Nelken</surname><given-names>NA</given-names></name><name><surname>Coughlin</surname><given-names>SR</given-names></name><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Schall</surname><given-names>TJ</given-names></name></person-group><article-title>Local expression of inflammatory cytokines in human atherosclerotic plaques.</article-title><source>J Atheroscler Thromb</source><year>1994</year><issue>Suppl 1</issue><fpage>S10</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">9222884</pub-id></citation></ref><ref id="r69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veillard</surname><given-names>NR</given-names></name><name><surname>Kwak</surname><given-names>B</given-names></name><name><surname>Pelli</surname><given-names>G</given-names></name><name><surname>Mulhaupt</surname><given-names>F</given-names></name><name><surname>James</surname><given-names>RW</given-names></name><name><surname>Proudfoot</surname><given-names>AE</given-names></name><name><surname>Mach</surname><given-names>F</given-names></name></person-group><article-title>Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice.</article-title><source>Circ Res</source><year>2004</year><volume>94</volume><fpage>253</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">14656931</pub-id></citation></ref><ref id="r70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nickel</surname><given-names>RG</given-names></name><name><surname>Casolaro</surname><given-names>V</given-names></name><name><surname>Wahn</surname><given-names>U</given-names></name><name><surname>Beyer</surname><given-names>K</given-names></name><name><surname>Barnes</surname><given-names>KC</given-names></name><name><surname>Plunkett</surname><given-names>BS</given-names></name><name><surname>Freidhoff</surname><given-names>LR</given-names></name><name><surname>Sengler</surname><given-names>C</given-names></name><name><surname>Plitt</surname><given-names>JR</given-names></name><name><surname>Schleimer</surname><given-names>RP</given-names></name><name><surname>Caraballo</surname><given-names>L</given-names></name><name><surname>Naidu</surname><given-names>RP</given-names></name><name><surname>Levett</surname><given-names>PN</given-names></name><name><surname>Beaty</surname><given-names>TH</given-names></name><name><surname>Huang</surname><given-names>SK</given-names></name></person-group><article-title>Atopic dermatitis is associated with a functional mutation in the promoter of the C&#x02013;C chemokine RANTES.</article-title><source>J Immunol</source><year>2000</year><volume>164</volume><fpage>1612</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10640782</pub-id></citation></ref><ref id="r71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rockman</surname><given-names>MV</given-names></name><name><surname>Hahn</surname><given-names>MW</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Goldstein</surname><given-names>DB</given-names></name><name><surname>Wray</surname><given-names>GA</given-names></name></person-group><article-title>Positive selection on a human-specific transcription factor binding site regulating IL4 expression.</article-title><source>Curr Biol</source><year>2003</year><volume>13</volume><fpage>2118</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">14654003</pub-id></citation></ref><ref id="r72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Winkelmann</surname><given-names>BR</given-names></name><name><surname>Hoffmann</surname><given-names>MM</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>BO</given-names></name><name><surname>Wieland</surname><given-names>H</given-names></name><name><surname>M&#x000e4;rz</surname><given-names>W</given-names></name></person-group><article-title>The interleukin-6 G(&#x02212;174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction.</article-title><source>J Mol Med</source><year>2002</year><volume>80</volume><fpage>507</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12185451</pub-id></citation></ref><ref id="r73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langsenlehner</surname><given-names>U</given-names></name><name><surname>Krippl</surname><given-names>B</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>Yazdani-Biuki</surname><given-names>B</given-names></name><name><surname>Eder</surname><given-names>T</given-names></name><name><surname>K&#x000f6;ppel</surname><given-names>H</given-names></name><name><surname>Wascher</surname><given-names>TC</given-names></name><name><surname>Paulweber</surname><given-names>B</given-names></name><name><surname>Samonigg</surname><given-names>H</given-names></name></person-group><article-title>Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk.</article-title><source>Breast Cancer Res Treat</source><year>2005</year><volume>90</volume><fpage>113</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15803357</pub-id></citation></ref><ref id="r74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Shabrawi</surname><given-names>Y</given-names></name><name><surname>Wegscheider</surname><given-names>BJ</given-names></name><name><surname>Weger</surname><given-names>M</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>Posch</surname><given-names>U</given-names></name><name><surname>Ulrich</surname><given-names>S</given-names></name><name><surname>Ardjomand</surname><given-names>N</given-names></name><name><surname>Hermann</surname><given-names>J</given-names></name></person-group><article-title>Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27 associated uveitis: association with susceptibility and clinical manifestations.</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>695</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">16581430</pub-id></citation></ref><ref id="r75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wegscheider</surname><given-names>BJ</given-names></name><name><surname>Weger</surname><given-names>M</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>Posch</surname><given-names>U</given-names></name><name><surname>Ulrich</surname><given-names>S</given-names></name><name><surname>Hermann</surname><given-names>J</given-names></name><name><surname>Ardjomand</surname><given-names>N</given-names></name><name><surname>Haller-Schober</surname><given-names>EM</given-names></name><name><surname>El-Shabrawi</surname><given-names>Y</given-names></name></person-group><article-title>Role of the CCL2/MCP-1 &#x02212;2518A&#x0003e;G gene polymorphism in HLA-B27 associated uveitis.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>896</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">16280979</pub-id></citation></ref><ref id="r76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goverdhan</surname><given-names>SV</given-names></name><name><surname>Ennis</surname><given-names>S</given-names></name><name><surname>Hannan</surname><given-names>SR</given-names></name><name><surname>Madhusudhana</surname><given-names>KC</given-names></name><name><surname>Cree</surname><given-names>AJ</given-names></name><name><surname>Luff</surname><given-names>AJ</given-names></name><name><surname>Lotery</surname><given-names>AJ</given-names></name></person-group><article-title>Interleukin-8 promoter polymorphism &#x02212;251A/T is a risk factor for age-related macular degeneration.</article-title><source>Br J Ophthalmol</source><year>2008</year><volume>92</volume><fpage>537</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">18310311</pub-id></citation></ref><ref id="r77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simeoni</surname><given-names>E</given-names></name><name><surname>Winkelmann</surname><given-names>BR</given-names></name><name><surname>Hoffmann</surname><given-names>MM</given-names></name><name><surname>Fleury</surname><given-names>S</given-names></name><name><surname>Ruiz</surname><given-names>J</given-names></name><name><surname>Kappenberger</surname><given-names>L</given-names></name><name><surname>M&#x000e4;rz</surname><given-names>W</given-names></name><name><surname>Vassalli</surname><given-names>G</given-names></name></person-group><article-title>Association of RANTES G-403A gene polymorphism with increased risk of coronary atherosclerosis.</article-title><source>Eur Heart J</source><year>2004</year><volume>25</volume><fpage>1438</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15302103</pub-id></citation></ref><ref id="r78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreotti</surname><given-names>F</given-names></name><name><surname>Porto</surname><given-names>I</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Maseri</surname><given-names>A</given-names></name></person-group><article-title>Inflammatory gene polymorphisms and ischemic heart disease: review of population association studies.</article-title><source>Heart</source><year>2002</year><volume>87</volume><fpage>107</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">11796541</pub-id></citation></ref><ref id="r79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vendrell</surname><given-names>J</given-names></name><name><surname>Fernandez-Real</surname><given-names>JM</given-names></name><name><surname>Gutierrez</surname><given-names>C</given-names></name><name><surname>Zamora</surname><given-names>A</given-names></name><name><surname>Simon</surname><given-names>I</given-names></name><name><surname>Bardaji</surname><given-names>A</given-names></name><name><surname>Ricart</surname><given-names>W</given-names></name><name><surname>Richart</surname><given-names>C</given-names></name></person-group><article-title>A polymorphism in the promoter region of the tumor necrosis factor-alpha gene (&#x02212;308) is associated with coronary heart disease in type 2 diabetic patients.</article-title><source>Atherosclerosis</source><year>2003</year><volume>167</volume><fpage>257</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">12818408</pub-id></citation></ref><ref id="r80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>V</given-names></name><name><surname>Pillois</surname><given-names>X</given-names></name><name><surname>Dubus</surname><given-names>I</given-names></name><name><surname>Benchimol</surname><given-names>D</given-names></name><name><surname>Labouyrie</surname><given-names>JP</given-names></name><name><surname>Couffinhal</surname><given-names>T</given-names></name><name><surname>Coste</surname><given-names>P</given-names></name><name><surname>Bonnet</surname><given-names>J</given-names></name></person-group><article-title>The &#x02212;308 G/A tumor necrosis factor-alpha gene dimorphism: a risk factor for unstable angina.</article-title><source>Clin Chem Lab Med</source><year>2003</year><volume>41</volume><fpage>511</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12747595</pub-id></citation></ref><ref id="r81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sbarsi</surname><given-names>I</given-names></name><name><surname>Falcone</surname><given-names>C</given-names></name><name><surname>Boiocchi</surname><given-names>C</given-names></name><name><surname>Campo</surname><given-names>I</given-names></name><name><surname>Zorzetto</surname><given-names>M</given-names></name><name><surname>De Silvestri</surname><given-names>A</given-names></name><name><surname>Cuccia</surname><given-names>M</given-names></name></person-group><article-title>Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease.</article-title><source>Int J Immunopathol Pharmacol</source><year>2007</year><volume>20</volume><fpage>145</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">17346438</pub-id></citation></ref><ref id="r82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>Y</given-names></name><name><surname>Chae</surname><given-names>JS</given-names></name><name><surname>Hyun</surname><given-names>YJ</given-names></name><name><surname>Koh</surname><given-names>SJ</given-names></name><name><surname>Ko</surname><given-names>MJ</given-names></name><name><surname>Rim</surname><given-names>SJ</given-names></name><name><surname>Shin</surname><given-names>HJ</given-names></name><name><surname>Ordovas</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>The RANTES &#x02212;403G&#x0003e;A promoter polymorphism in Korean men: association with serum RANTES concentrations and coronary artery disease.</article-title><source>Clin Sci (Lond)</source><year>2007</year><volume>113</volume><fpage>349</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">17504241</pub-id></citation></ref><ref id="r83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rundek</surname><given-names>T</given-names></name><name><surname>Elkind</surname><given-names>MS</given-names></name><name><surname>Pittman</surname><given-names>J</given-names></name><name><surname>Boden-Albala</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Juo</surname><given-names>SH</given-names></name><name><surname>Sacco</surname><given-names>RL</given-names></name></person-group><article-title>Carotid intima-media thickness is associated with allelic variants of stromeolysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study.</article-title><source>Stroke</source><year>2002</year><volume>33</volume><fpage>1420</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">11988625</pub-id></citation></ref><ref id="r84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group><article-title>Why most published research findings are false.</article-title><source>PLoS Med</source><year>2005</year><volume>2</volume><fpage>e124</fpage><pub-id pub-id-type="pmid">16060722</pub-id></citation></ref></ref-list></back></article> 